Stock Price, News, Quote and Profile of VERVE THERAPEUTICS INC(NASDAQ:VERV) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

VERVE THERAPEUTICS INC

NASDAQ:VERV (5/3/2024, 7:24:35 PM)

After market: 6.41 0 (0%)

6.41

+0.26 (+4.23%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap537.93M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular disease. The company is headquartered in Boston, Massachusetts and currently employs 204 full-time employees. The company went IPO on 2021-06-17. The Company’s programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. The company is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second product candidate VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a regulator of cholesterol and triglyceride metabolism.

Company Info

VERVE THERAPEUTICS INC

201 Brookline Avenue, Suite 601

Boston MASSACHUSETTS

P: 19785013026

CEO: Sekar Kathiresan

Employees: 204

Website: https://www.vervetx.com/

VERV News

2 days ago - Verve TherapeuticsVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of...

17 days ago - Wolf Haldenstein Adler Freeman & Herz LLPWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws

/PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is...